A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)

Name: A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Published: 2014
License: Public Domain

Merck Sharp & Dohme LLC · 2014

ClinicalTrials.gov · Datasets · License: Public Domain · 2014

Open Source ↗

urothelial cancer, programmed cell death-1 (pd1, pd-1), programmed death-ligand 1 (pdl1, pd-l1), bladder cancer, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)

Related documents